Dren Bio
Agent35Agent Readiness: 35/100. Below median. Measured by StartupHub.ai. Median 41.Biopharmaceutical company developing antibody therapeutics for cancer and autoimmune diseases.
About
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics that selectively deplete pathogenic cells and disease-causing agents. Their proprietary Targeted Myeloid Engager and Phagocytosis Platform underpins their pipeline of first-in-class clinical and preclinical programs targeting oncology, autoimmune diseases, immunology, and neurology. Dren Bio aims to redefine treatment possibilities for patients with cancer and other serious diseases.
Key facts
At-a-glance profile data
- Website
- drenbio.com
- Headquarters
- San Carlos, United States
- Founded
- 2019
- Total funding
- $156M (Venture Round)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 24 Jul 2024 | Venture Round | $25M | - |
| 28 Mar 2022 | Series B | $65M | HBM Healthcare Investments |
| 16 Oct 2020 | Series A | $60M | SR One, Taiho Ventures LLC |
| 1 Jan 2019 | Seed | $6M | 8VC |
Tech stack
Detected on drenbio.com, last scanned 21 Sept 2026. Run your own scan
- Frontend
- Tailwind CSS, Bootstrap
- Analytics
- Google Analytics 4, Google Tag Manager
- Email provider
- Microsoft 365
Frequently asked
How much funding has Dren Bio raised?
Dren Bio has raised a total of $156M in funding. The most recent round on record is Venture Round.